For individuals who cannot tolerate the gastrointestinal side effects of GLP-1 agonists, or who are seeking a compound with minimal systemic hormonal activity, AOD-9604's safety record is one of its few genuine selling points
For the most part, AOD-9604 is considered to be safe and well tolerated, with few side effects being reported in research studies
General PA criteria include: BMI threshold: BMI 30 (obesity), or BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease) Documentation of medical necessity: Clinical notes confirming obesity diagnosis, comorbidities, and treatment rationale from a licensed provider Prior lifestyle program participation: Many plans require documentation of participation in a structured diet and exercise program for a defined period (typically 36 months) before GLP-1 medications are authorized Non-diabetic indication: For Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide weight loss dose), the weight management indication must be documented separately from diabetes management Step therapy: Some Cigna plans may require an oral agent (such as phentermine or Contrave) trial before authorizing higher-cost GLP-1 medications Ongoing authorization: GLP-1 PA approvals are typically renewable annually and may require documentation of 5% body weight reduction to continue coverage Klarity Healths clinical team may assist with the prior authorization process
J Affect Disord 2011;135:389-94
